Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis

被引：6

作者：

Yi, Jun Ho ^{[1
]}

Kim, Seok Jin ^{[2
]}

Yoon, Dok Hyun ^{[3
]}

Suh, Cheolwon ^{[3
]}

Chang, Myung Hee ^{[4
]}

Yang, Deok Hwan ^{[5
]}

Jo, Jae-Cheol ^{[6
]}

Hyun, Shin Young ^{[7
]}

Eom, Hyeon-Seok ^{[8
]}

Lee, Jeong-Ok ^{[9
]}

Kwon, Ji Hyun ^{[10
]}

Han, Sang Hoon ^{[11
]}

Lee, Seung-Shin ^{[12
]}

Kwak, Jae-Yong ^{[13
]}

Kim, Se Hyung ^{[14
]}

Kim, Dae Sik ^{[15
]}

Lee, Ji Hyun ^{[16
]}

Oh, Sung Yong ^{[16
]}

Ryoo, Hun Mo ^{[17
]}

Kim, Hyo Jung ^{[18
]}

Kim, Won Seog ^{[2
]}

机构：

[1] Chung Ang Univ, Div Hematol Oncol, Dept Med, Seoul 06973, South Korea

[2] Sungkyunkwan Univ, Div Hematol & Oncol, Dept Med, Samsung Med Ctr,Sch Med, 50 Irwon Dong, Seoul 06351, South Korea

[3] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul 05505, South Korea

[4] Natl Hlth Insurance Corp Ilsan Hosp, Goyang 10444, South Korea

[5] Chonnam Natl Univ, Sch Med, Dept Hematooncol, Hwasun Hosp, Hwasun 58128, Gwangju, South Korea

[6] Univ Ulsan, Dept Hematol & Oncol, Ulsan Univ Hosp, Coll Med, Ulsan 44033, South Korea

[7] Yonsei Univ, Dept Internal Med, Coll Med, Wonju 26426, South Korea

[8] Natl Canc Ctr, Dept Internal Med, Gyeonggi Do 10408, Goyang, South Korea

[9] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam 13620, South Korea

[10] ChungBuk Natl Univ Hosp, Dept Internal Med, Chungbuk 28644, Cheongju, South Korea

[11] Jeju Natl Univ, Dept Internal Med, Jeju Natl Univ Hosp, Sch Med, Jeju 63241, South Korea

[12] Wonkwang Univ Hosp, Dept Hematol Oncol, Iksan 54538, South Korea

[13] Jeonbuk Natl Univ, Dept Internal Med, Sch Med, Jeonju 54907, South Korea

[14] Soonchunhyang Univ, Div Hematol Oncol, Dept Internal Med, Coll Med,Bucheon Hosp, Bucheon 14584, South Korea

[15] Korea Univ, Div Hematol Oncol, Dept Internal Med, Guro Hosp, Seoul 08308, South Korea

[16] Dong A Univ, Div Hematol Oncol, Dept Internal Med, Coll Med, Busan 49201, South Korea

[17] Catholic Univ Daegu, Dept Internal Med, Div Hematol Oncol, Daegu 42472, South Korea

[18] Hallym Univ, Div Hematol Oncol, Dept Internal Med, Sacred Heart Hosp,Coll Med, Anyang 14068, South Korea

来源：

CANCER COMMUNICATIONS | 2021年 / 41卷 / 03期

关键词：

D O I：

10.1002/cac2.12150

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：275 / 278

页数：4

共 10 条

[1] Broccoli Alessandro, 2018, Oncotarget, V9, P23443, DOI 10.18632/oncotarget.25215
[2] Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study
Epperla, Narendranath
Hamadani, Mehdi
Cashen, Amanda F.
Ahn, Kwang W.
Oak, Eunhye
Kanate, Abraham S.
Calzada, Oscar
Cohen, Jonathon B.
Farmer, Luke
Ghosh, Nilanjan
Tallarico, Michael
Nabhan, Chadi
Costa, Luciano J.
Kenkre, Vaishalee P.
Hari, Parameswaran N.
Fenske, Timothy S.
[J]. HEMATOLOGICAL ONCOLOGY, 2017, 35 (04) : 528 - 535
[3] A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Hoster, Eva
Dreyling, Martin
Klapper, Wolfram
Gisselbrecht, Christian
van Hoof, Achiel
Kluin-Nelemans, Hanneke C.
Pfreundschuh, Michael
Reiser, Marcel
Metzner, Bernd
Einsele, Hermann
Peter, Norma
Jung, Wolfram
Woermann, Bernhard
Ludwig, Wolf-Dieter
Duehrsen, Ulrich
Eimermacher, Hartmut
Wandt, Hannes
Hasford, Joerg
Hiddemann, Wolfgang
Unterhalt, Michael
[J]. BLOOD, 2008, 111 (02) : 558 - 565
[4] le Du Katell, 24 EUR HEM ASS ANN C
[5] Nationwide Statistical Analysis of Lymphoid Malignancies in Korea
Lee, Hyewon
Park, Hyeon Jin
Park, Eun-Hye
Ju, Hee Young
Oh, Chang-Mo
Kong, Hyun-Joo
Jung, Kyu-Won
Park, Byung-Kiu
Lee, Eunyoung
Eom, Hyeon-Seok
Won, Young-Joo
[J]. CANCER RESEARCH AND TREATMENT, 2018, 50 (01): : 222 - 238
[6] Postibrutinib outcomes in patients with mantle cell lymphoma
Martin, Peter
Maddocks, Kami
Leonard, John P.
Ruan, Jia
Goy, Andre
Wagner-Johnston, Nina
Rule, Simon
Advani, Ranjana
Iberri, David
Phillips, Tycel
Spurgeon, Stephen
Kozin, Eliana
Noto, Katherine
Chen, Zhengming
Jurczak, Wojciech
Auer, Rebecca
Chmielowska, Ewa
Stilgenbauer, Stephan
Bloehdorn, Johannes
Portell, Craig
Williams, Michael E.
Dreyling, Martin
Barr, Paul M.
Chen-Kiang, Selina
DiLiberto, Maurizio
Furman, Richard R.
Blum, Kristie A.
[J]. BLOOD, 2016, 127 (12) : 1559 - 1563
[7] Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis
Rule, Simon
Dreyling, Martin
Goy, Andre
Hess, Georg
Auer, Rebecca
Kahl, Brad
Hernandez-Rivas, Jose-Angel
Qi, Keqin
Deshpande, Sanjay
Parisi, Lori
Wang, Michael
[J]. HAEMATOLOGICA, 2019, 104 (05) : E211 - E214
[8] Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study
Sharman, Jeff
Kabadi, Shaum M.
Clark, Jamyia
Andorsky, David
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (04) : 737 - 746
[9] Distribution of Lymphoid Neoplasms in China Analysis of 4,638 Cases According to the World Health Organization Classification
Sun, Jian
Yang, Qunpei
Lu, Zhaohui
He, Miaoxia
Gao, Li
Zhu, Minghua
Sun, Lu
Wei, Lixin
Li, Min
Liu, Cuiling
Zheng, Jie
Liu, Weiping
Li, Gandi
Chen, Jie
[J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2012, 138 (03) : 429 - 434
[10] Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group
Yoon, Dok Hyun
Cao, Junning
Chen, Tsai-Yun
Izutsu, Koji
Kim, Seok Jin
Kwong, Yok Lam
Lin, Tong Yu
Thye, Lim Soon
Xu, Bing
Yang, Deok Hwan
Kim, Won Seog
[J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)

← 1 →